Biotech Values

[DewDiligence]

>TEVA/Amphastar: Wouldn't any anti-trust case infer that monetary damages are due despite no approved generic product? Or, perhaps, that the FDA was complicit by not approving a generic based on the existing patent, thus "constructively" blocking sales? Seems like a long stretch, or is there precedent?<

Good questions, but I don’t know enough about anti-trust precedents to answer.

The remark in the ft.com article that I question is the assertion that treble damages will automatically ensue if SNY is found at fault.

Edit: I see that zipjet posted some color about treble damages. Agree that SNY ought to be worried about it.